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report other groups from the Massachusetts General
Hospital,1 the Mayo Clinic,2 and the Memorial Sloan-
Kettering Cancer Center3 have confirmed the accept-
able morbidity and mortality of this approach and
have stressed the survival benefit in a significant per-
centage of these patients. It is generally believed that
survival after resection of an NSCLC invading the
chest wall is significantly related to the completeness
of resection and to the lymph node involvement.2,3,5,6
In our opinion en bloc resection, without opening the
extrapleural space and avoiding exposure of tumor, is
the procedure of choice to achieve a complete resec-
tion (R0). This article reports our homogeneous expe-
rience with 104 R0 en bloc resections mostly per-
formed by the same surgeon with the same technique
in a 9-year period.
Approximately 5% to 8%1-3 of patients undergoingresection for non–small cell lung carcinoma
(NSCLC) have involvement of parietal pleura, soft
tissue, intercostal muscles, or ribs. Coleman4 in 1947
first reported long-term survival after en bloc excision
of the chest wall with pulmonary resection. Since that
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Methods
From January 1, 1990, to June 30, 1999, 12,059 patients
were admitted to the Division of Thoracic Surgery, Carlo
Forlanini Hospital, in Rome. Of these, 1855 patients under-
went major pulmonary resections (Current Procedural
Terminology codes 32440-32445 and 32480-32488) for
NSCLC. In 104 patients (5.60%) with NSCLC invading the
parietal pleura or chest wall, en bloc resection of the chest
wall and lung parenchyma plus routine systematic dissec-
tion of all hilar and mediastinal nodes was performed.
Indications for chest wall resection were chest pain and
computed tomographic (CT) or magnetic resonance imag-
ing (MRI) evidence of chest wall invasion intraoperatively
confirmed by parietal pleural attachment of a peripheral
NSCLC tumor.
En bloc resection of the chest wall and lung was defined as
removal of lung parenchyma in continuity with parietal pleu-
ra and chest wall soft tissue with bony structures without
removal of the overlying integument. Extrapleural resection
was defined as extrapleural dissection of the tumor from the
chest wall with removal of lung parenchyma and of a portion
of the overlying parietal pleura. A complete resection (R0)
was defined as pathologic evidence of disease-free (negative)
tissue margins and an assessment by the operating surgeon
that all grossly detectable disease had been removed. Patients
with Pancoast tumor and patients whose tumor invaded the
thoracic spine were excluded.
All patients were routinely evaluated with a thorough med-
ical history, physical examination, complete blood cell count,
blood chemistry, liver function test, respiratory function test,
and electrocardiogram and underwent chest radiography, total
body CT scan, MRI, and fiberoptic bronchoscopy. 
Operative mortality was defined as mortality within 30
days or within the same hospitalization. Histologic typing
was conducted according to the International Classification
of Disease for Oncology.7
Statistics. Crude survival proportions were calculated by
the method of Kaplan and Meier.8 Differences in survival dis-
tribution were tested with the log-rank test. Multivariate
analysis was done by the Cox model.
Operative technique. The great majority of the operations
(94/104) was performed by the same surgeon (F.F.), who used
the following surgical approach: The chest cavity is entered
posterolaterally. Depending on the level of involvement, it is
possible to tailor the incision for more effect. Within the
pleural cavity, the limits of chest wall invasion and the state
of the hilar and mediastinal nodes are explored to ascertain
operability and to define the margins of resection. The mar-
gins of resection should include an uninvolved rib and inter-
costal space above and below.9 The ribs are divided at a safe
distance from the tumor, at least 4 cm.10 The transection starts
with the lowest rib, each preceded by ligation and transection
of the intercostal vessels. Special attention is paid to the
region of tumor attachment to the vertebral bodies.
Transection of ribs must at times be flush with the vertebral
bodies, through the costotransverse joints. The resected por-
tion of the chest wall attached to the lung is then allowed to
drop into the pleural cavity, where pulmonary resection is
performed in the usual manner and associated with a radical
standard lymphadenectomy. Closure is accomplished with
either scapular or chest wall musculature.
Results 
The demographic features and treatment data are
shown in Table I. In 37 patients with suspected radio-
logic N2 disease (mediastinal lymph nodes 12 mm or
more in largest diameter), mediastinoscopy or anterior
mediastinotomy was performed. Of these patients, 6
had histologically proven N2 disease and underwent
preoperative induction therapy (chemotherapy only).
Transparietal fine needle aspiration biopsy was per-
formed in 49 patients and yielded a positive result in 38
(77.55%). 
No attempt at extrapleural dissection was made in the
present series of 104 patients. Only the presence of
filmy adhesions with a clear plane between the viscer-
al and parietal pleura precluded chest wall resection. In
such cases (49 patients), not reported in the present
series, extrapleural dissection in the area of filmy adhe-
sions was done and no microscopic parietal pleural
involvement was detected.
All patients underwent R0 radical en bloc resection
with microscopically negative tissue margins and intra-
operative assessment of removal of all detectable dis-
ease. Histologic features were reviewed at the time of
the study, with emphasis on the depth of tumor invasion
and degree of lymph node involvement. In all patients
the pathologic stage was T3. The pathologic depth of
invasion was into the parietal pleura alone in 28
(26.92%) patients, into the parietal pleura and soft tis-
sue in 36 (34.62%) patients, and into the parietal pleu-
ra, soft tissue, and bone in 40 (38.46%) patients.
Resection margins were less than 3 mm in 1 patient,
between 3 mm and 1 cm in 3 patients, between 1 cm
and 2 cm in 11 patients, and more than 2 cm in the
remaining 89 patients. The mean number of resected
lymph nodes per patient was 15.8 ± 9.6. All lymph
nodes were negative (N0) in 83 (79.81%) patients, 5
(4.81%) patients had diseased (positive) N1 nodes, and
16 (15.38%) patients had positive N2 nodes. Prosthetic
reconstruction of the costal wall was not performed. 
No operative mortality was reported. Mean hospital
stay was 12.3 ± 4.5 days. Major complications
occurred in 20 (19.23%) patients and included atrial
fibrillation in 5 patients, bleeding that necessitated
reoperation in 2 patients, transient spinal fluid leak in 1
patient, prolonged (>6 days) air leak in 8 patients,
pleural empyema in 2 patients, bronchopleural fistula
in 1 patient, and entrapment of the scapula during
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movement of the arm in 1 patient. Spinal fluid leak and
prolonged air leak resolved spontaneously. Broncho-
pleural fistula was successfully treated endoscopically.
The patient with entrapment of the scapula underwent
resection of the tip of the scapula. 
Forty-two patients received postoperative radiothera-
py (average dose, 35 Gy). Patients with positive N2
lymph nodes were given postoperative chemotherapy.
All patients were entered in the follow-up program,
which included clinical examination and chest radiog-
raphy 1 and 3 months after the operation. Six months
after the operation and every 6 months thereafter, a
total body CT scan was performed. Follow-up ended
April 25, 2000. The median length of follow-up was
25.5 months (range 10-120 months). Eight patients
were lost to follow-up and were not considered in this
study: Four of these patients were alive and free of dis-
ease 14, 16, 29, and 38 months after their operations,
when they disappeared from our database; 3 patients
refused further follow-up 6 months after the operation;
and 1 patient moved to another country and did not for-
ward information regarding his health status. Ninety-
six patients completed the follow-up program with at
least 1 total body CT scan performed within the past 6
months.
One patient had a local recurrence 17 months after
the operation. Pathologic review of the surgical speci-
men showed close margins (<3 mm). This patient
underwent radiotherapy and chemotherapy and is still
alive with disease 22 months after the operation.
The overall 5-year Kaplan-Meier estimated survival
in 96 patients who completed the follow-up was 61.4%
with a median survival of 74 months. The 5-year esti-
mated survival of patients with T3 N0 M0 disease was
67.3% (77 patients), with a median of 74 months; in
those with T3 N1 M0 disease, 100% (only 5 patients);
and in those with T3 N2 M0 disease (14 patients),
17.9%, with a median survival of 23 months. The dif-
ference in survival between N0 and N2 is highly sig-
nificant by log-rank test (P = .007) (Fig 1 and Table II).
Five-year estimated survival was 71.8% in squamous
cell carcinoma and 53.0% in adenocarcinoma. There
was no statistically significant difference by log-rank
test (P = .329 (Table II). Five-year estimated survival
was 60.8% in men and 70.7% in women (P = .573).
Regarding the pathologic depth of invasion, the 5-
year estimated survival was 79.1% with a median sur-
vival of 74 months in 26 patients with involvement of
the parietal pleura only (2 patients were lost to follow-
up); the overall 5-year survival was 52.1% in 33
patients with involvement of the parietal pleura and
soft tissue (3 patients lost to follow-up); the overall 5-
year survival was 56.4% in 37 patients (3 patients lost
to follow-up) with involvement of parietal pleura, soft
tissue, and bone. Depth of cell wall invasion showed a
statistically significant difference by log-rank test 
(P = .037). The cumulative 5-year survival in 70
patients with involvement of soft tissue, with or with-
out bone invasion, was 54.0% (P = .014) (Table II).
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Table I.  Demographic features and treatment data 
in 104 patients
No. of patients 104
Men 90 (85.5%)
Women 14 (14.5%)
Ratio 6.42
Age (y)
Mean 62.9 ± 9.73
Range 35-80
>65 y 42
>75 y 7
Location
Right 64 (61.5%)
Left 40 (38.5%)
Symptoms
Chest pain 41 (39.4%)
Dyspnea 11 (10.6%)
Weight loss 10 (9.6%)
No. of smokers 69 (66.3)
Packs/year 170
Preoperative treatment
Chemotherapy only 6 (5.7%)
Radiation only —
Radiation + chemotherapy —
Histologic type
Squamous cell carcinoma 56 (53.9%)
Adenocarcinoma 42 (40.3%)
Adenosquamous carcinoma 3 (2.9%)
Large cell carcinoma 3 (2.9%)
Tumor diameter (cm)
Range 2-16.5
Type of operation
Pulmonary resection
Lobectomy 72 (69.3%)
Right upper 35
Left upper 29
Right inferior 4
Left inferior 4
Bilobectomy 15 (14.4%)
Superior/middle 15
Pneumonectomy 10 (9.6%)
Right 2
Left 8
Wedge/segmentectomy 7 (6.7%)
Chest wall resection 
5 ribs* 1 (0.96%)
4 ribs 30 (28.85%)
3 ribs 44 (42.31%)
2 ribs 26 (25%)
1 rib 3 (2.88%)
*Plus scapular tip.
The subset pN0 with parietal pleural involvement
only (22 patients) showed a 90.3% 5-year estimated
survival with a median survival of 96 months; the sub-
set pN0 with soft tissue involvement with or without
bone invasion (55 patients) showed 55.9% 5-year sur-
vival (P = .010). The overall 5-year estimated survival
for right lung neoplasms was 63.6% and the overall
estimated survival for left lung neoplasms was 58.0%.
There was no statistically significant difference
between right and left lung neoplasms (P = .808).
The overall 5-year estimated survival for patients
who underwent radiation therapy was 74.1%, whereas
in patients who did not undergo radiation therapy it was
46.7%. A statistically significant difference was mea-
sured by log-rank test (P = .023) (Table II).
The effect of each factor on the 5-year survival was
estimated by multivariate analysis by using the Cox
analysis. The final model included 4 variables: N sta-
tus, pathologic depth of chest wall invasion, histology,
and postoperative radiation therapy. Only N0 status and
involvement of parietal pleura were significantly linked
to a better prognosis. Squamous cell carcinoma com-
pared with adenocarcinoma and postoperative radiation
therapy compared with no radiotherapy did not show
any significant difference.
At the end of follow-up, 51 (49.04%) patients were
alive without evidence of disease, 12 (11.53%) patients
were alive with disease (local recurrence in 1 patient,
regional recurrence in 2 patients, and distant recurrence
in 9 patients), 10 (9.62%) patients died without evi-
dence of disease, and 23 (22.12%) died of metastatic
disease. Eight patients (7.69%) lost to follow-up have
been excluded from this analysis.
Discussion
The assessment of chest wall invasion by an NSCLC
is still a matter of debate. Preoperative evaluations (chest
x-ray films, ultrasound examinations, CT scan, and
MRI) lack specificity and sensitivity except in the pres-
ence of extensive bone destruction.11,12 Although persis-
tent localized chest pain in a patient with a peripheral
lung neoplasm is a strong indication of chest wall
involvement, the absence of pain does not exclude such
a possibility, in that 3 (7.5%) of 40 patients with tumor
extending to the periosteum and bone did not have pain. 
The lack of adherence of the tumor to the parietal
pleura at operation effectively excludes invasion of the
chest wall. Only filmy adhesions with a clear plane
between parietal and visceral pleura can be safely
divided.6
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Table II.  Five-year survival rates and hazard ratios with 95% confidence intervals by clinical and 
histopathologic features
Five-year Median Hazard
n % survival (%) P value* survival time (mo) ratio† 95% CI P value‡
Study patients 96
Sex
Male 85 88.5 60.8 74
Female 11 11.5 70.7 .573 96
Histologic type
Squamous cell carcinoma 52 57.8 71.8 74 1.00
Adenocarcinoma 38 42.2 53.0 .329 — 1.72 0.79-3.76 .174
Staging
N0 77 84.6 67.3 74 1.00
N2 14 15.6 17.9 .007 23 3.09 1.27-7.55 .013
Level of invasion 1
Parietal pleura 26 27.1 79.1 74
Soft tissue 33 34.4 52.1 —
Bone 37 38.5 56.4 .037 —
Level of invasion 2
Parietal pleura 26 27.1 79.1 74 1.00
Soft tissue + bone 70 72.9 54.0 .014 — 3.16 1.18-8.46 .022
Radiation therapy
No 47 49.0 46.7 50 1.00
Yes 49 51.0 74.1 .023 74 0.47 0.21-1.04 .064
CI, Confidence interval.
*Log-rank test.
†Final Cox regression model includes histologic type, staging, level of invasion, and radiation therapy.
‡Wald test.
If a tumor is found at operation to be adherent to the
parietal pleura, intraoperative assessment of chest wall
invasion represents a challenge both for the thoracic
surgeon and for the pathologist, and controversy exists
over the management of such tumors. In the past, some
surgeons believed that parietal pleura is a barrier to
tumor invasion and claimed that en bloc resection was
an unnecessary operation.13 Provided that en bloc
resection can be safely performed without significant
increase of morbidity or mortality,2,5,6 nowadays this
view has changed.
Most surgeons perform extrapleural dissection until
they find clear-cut (macroscopic or microscopic) evi-
dence of chest wall invasion.5 The assessment of a
tumor-free plane represents a subjective evaluation and
is related more to the experience of the surgeon than to
objective criteria. Frozen section histologic studies can
rarely help the surgeon in making the decision to resect
or not to resect the chest wall. According to such crite-
ria, the number of incomplete resections and the likeli-
hood of local recurrence are high.6,14 Even if the long-
term survival in NSCLC is highly related to the nodal
status, the completeness of resection still affects sur-
vival.2,5,6,15
In the series reported by Albertucci and coauthors,6
the rate of local recurrence was significantly lower in
patients undergoing en bloc chest wall resection than in
patients undergoing extrapleural resection (9.5% vs
37.5%, respectively), with a significant improvement in
survival in patients treated by en bloc chest wall resec-
tion. Trastek and associates16 reported an improved
survival when a chest wall resection was performed:
the 5-year actuarial survivals were 75% in chest wall
resection versus 28% in extrapleural resection. 
In the series reported by Downey and coworkers,5 the
overall 5-year survival in 175 patients with chest wall
invasion who underwent R0 resection was 32%, where-
as it was only 4% in 94 patients with chest wall
involvement who underwent incomplete (R1/R2)
resections. Our policy was to perform an en bloc resec-
tion in all of our 104 patients with parietal pleural
attachment of an NSCLC. Such an approach may look
too radical. Nevertheless, the complication rate
observed in our series (19.23%) was very similar to
that observed in the overall series of 1855 major pul-
monary resections performed at our institution. The 0%
operative mortality was remarkable if compared with
other reports in which the operative mortality ranged
from 2%3 to 15%.1,2,17 Moreover, we would like to
stress that our series, if compared with other reports
published in the literature, appears to be homogeneous:
around 90% of the operations (94/104) were performed
by the same surgeon in a relative short period (91⁄2
years) with a consistent and accurate follow-up. The
impressive 0% of positive margins with only 1 close
margin is the goal of such a radical approach. There
were no patients with microscopic tumor invasion lim-
ited to the visceral pleura, and in only 28 (26.92%)
patients was the invasion limited to the parietal pleura.
Only this very small group of patients could have safe-
ly undergone extrapleural resection. It is generally
believed that bony invasion can be easily ascertained
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Fig 1. Survival in patients with N0 vs N2 disease.
with CT/MRI examination,18 but evaluation of soft tis-
sue invasion represents a serious challenge: intraopera-
tive examination with frozen section underestimates the
degree of invasion and seems responsible for the high
rate of positive margins reported in some series favor-
ing extrapleural dissection as a first choice and reserv-
ing en bloc resection only to macroscopic evidence of
chest wall invasion.6,14 It is generally believed that an
incomplete resection (R1 or R2) offers the patient no
curative benefit independently from the nodal sta-
tus.5,6,14 Long-term survival is very similar in patients
having incomplete resection and those not undergoing
resection: 4% 3-year survival in patients having R1/R2
resection versus 0% in patients not having resection.5
The effort to obtain a microscopically negative margin
in every patient is the rationale for our radical approach
in tumor invading the chest wall. In our opinion, it is
better to offer an overtreatment to patients with tumor
limited to parietal pleura than to leave residual disease
in patients with tumor invading soft tissue and bone.
As the extent of the resection is concerned, lobecto-
my represented the procedure of choice in our series;
only 7 (6.73%) patients underwent wedge resection
because of respiratory insufficiency. The percentage of
wedge resection is in agreement with other reports: 3%
in the series by Piehler and colleagues,2 8.1% in the
series by Shah and Goldstraw,15 and 10% in the series
by Downey and associates.5 The percentage of pneu-
monectomies has been very low (11.53%) in our expe-
rience if compared with other series: 24% in the expe-
rience of Piehler and coworkers,2 20% in the
experience of Downey and colleagues,5 and 54.05% in
the experience of Albertucci and associates.6
Regarding sex as a prognostic factor, the small num-
ber of women in our series (14/104) does not allow us
to draw any conclusion in light of recent reports19,20
that support the hypothesis that hormonal status may
influence the prognosis in lung carcinoma.
The presence of mediastinal lymph node metastasis
significantly reduced the 5-year actuarial survival both
in our experience and in the previously reported series:
67.3% versus 17.9%, respectively, in N0 and N2 (P =
.007) in our cases; 49% versus 15% in the experience
of Downey and colleagues5; 41% versus 0% in the
experience of Albertucci and coworkers6; and 53.7%
versus 7.4% in the experience of Piehler and associ-
ates.2 The small number of N1 patients (5 cases) does
not allow us to comment regarding the 100% 5-year
actuarial survival. We could not find any statistically
significant effect on survival of age (<57, 58-65, 66-70,
or >71 years), histology, sex, tumor size, or location of
the tumor.
The depth of tumor invasion did significantly affect
prognosis independently from the nodal status. Similar
results have not been demonstrated in the recent expe-
rience of Downey’s group.5
If we match lymph node involvement and depth of
chest wall invasion, the subset pN0 with parietal pleur-
al involvement shows a 5-year estimated survival sig-
nificantly better than the subsets pN0 with soft tissue
involvement (with or without bone invasion): respec-
tively, 90.3% versus 55.9% (P = .010). In the subsets of
patients with soft tissue involvement, bone invasion has
not lowered prognosis (P = .489).
The indications for radiation therapy for chest wall
invasion are not well defined. Most of the series report-
ed in the literature2,5,14,21 did not find any improvement
in survival with radiotherapy. Patterson and associ-
ates22 reported an insignificant improvement in sur-
vival with radiation therapy. Our results showed a pos-
itive effect of radiation therapy on long-term survival,
even if the improvement was not statistically signifi-
cant with the Cox analysis (P = .064).
The choice to reconstruct the chest wall defect with
no prosthesis was mainly related to our large experi-
ence with muscular flaps. This approach was cost-
effective and avoided the use of synthetic material. No
respiratory complication or impairment of pulmonary
function was seen in our patients.
Concerning follow-up, only periodic total body CT
scan (with a range from 6 months to 1 year) may detect
early locoregional or distant recurrences. Most of the
previously reported series do not address the problem
of follow-up examinations. The policy of the Italian
Health System, which offers CT scans and clinical con-
sultations free of charge to patients with lung cancer,
probably enhances the patient’s acceptance.
In conclusion, in NSCLC invading chest wall, there
is no way to ascertain before or during surgery the
exact extent of tumor invasion through the chest wall;
the high percentage of invasion of soft tissue and bone
found in the pathologic review of the specimens report-
ed in the present series (76/104) justifies the routine use
of en bloc resection; the trial of extrapleural dissection
may expose the tumor and delay the timing of conver-
sion to chest wall resection; routine en bloc resection is
associated with the finding of microscopically negative
margins in almost all patients and with an acceptable
morbidity and mortality.
Furthermore, the present series emphasizes the need
of special technical skills in performing a somewhat
delicate surgical procedure: the great majority of the
procedures (90.38%) was performed by only one sur-
geon with special interest and training, and in a rela-
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tively short period of time, using the same technique in
all patients.
Prognosis is highly related to the completeness of
resection, the lymph node involvement, and the depth
of tumor invasion. The subset of patients with pT3
(parietal pleura only) N0 disease with microscopically
negative margins who underwent en bloc resection of
lung and chest wall showed in our experience an
impressive 90.3% 5-year estimated survival.
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Discussion
Dr Valerie W. Rusch (New York, NY). I congratulate you
on an excellent and interesting presentation. Although this
study does not present entirely new data, it nicely extends and
corroborates previous reports describing the surgical man-
agement of NSCLC invading the chest wall. You are to be
commended on your excellent results, relatively low morbid-
ity, and zero mortality. These results emphasize the impor-
tance of complete resection, the negative prognostic impact
of N2 disease, and the influence of depth of tumor penetra-
tion into the chest wall on survival. They also underscore that
the safest course of action is to perform a chest wall resection
in cases in which the extent of pleural involvement is in doubt
at the time of the operation, particularly if the operating sur-
geon does not have extensive experience in this type of pro-
cedure. 
You have suggested that postoperative low-dose radiation
may be beneficial, or at least that its impact on survival
approaches statistical significance. However, I would caution
that this conclusion is based on a small subset of patients
treated in an individualized manner and, on that basis, proba-
bly should be discounted. I would also remark that this find-
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ing is somewhat at odds with all other published information
regarding the use of adjuvant radiation. 
I have 4 questions. First, given the results of this study and
of previous reports, have you changed your policy regarding
mediastinoscopy? I noted that you did this selectively and
you now choose to perform this routinely in patients who
have T3 chest wall tumors. 
Second, have you modified your attitude about the use of
chest wall reconstruction given the low risk and excellent
results reported by other authors, including ourselves?
Posterior chest wall reconstruction, usually performed with a
2-mm thick polytetrafluoroethylene patch to provide support
to the scapula, particularly the tip of the scapula, is certainly
technically easy. It avoids the morbidity caused by the lack of
support of the tip of the scapula and certainly would avoid a
second operation to resect the tip of the scapula, as you had
to do in 1 case.
I noticed that you performed MRI preoperatively in a small
number of patients. Most of us do not do this routinely. Do
you continue to do preoperative MRI and, if so, why? 
Finally, because you have been able to identify what you
think is a group of patients with a somewhat poorer progno-
sis due to soft tissue or bony involvement, have you consid-
ered using induction chemotherapy or testing induction
chemotherapy as a routine approach in that group of patients? 
Dr Thomas W. Rice (Cleveland, Ohio). Your surgical phi-
losophy is to assume that the chest wall is involved. Would
you do an extrapleural dissection so long as there were no
filmy adhesions? In how many chest wall resections was there
no parietal pleural invasion? 
Dr Mark S. Allen (Rochester, Minn). In your presentation
you mentioned some patients with N2 disease, and you stated
in your abstract that you treated them preoperatively with
induction therapy. Could you describe what that was? I was
also impressed that you had a 30% or a 27% 5-year survival in
those patients. In the other reports emanating from other insti-
tutions, or at least from the Massachusetts General Hospital in
our series, the survivals were nowhere near that high. Could
you comment on that? Is there something special about the
group of patients with early chest wall invasion? Why did they
have such a good survival? What are you doing differently that
the rest of us can do to get that kind of cure rate? 
Dr Cardillo. The first question concerned medi-
astinoscopy. At our institution we do not perform many medi-
astinoscopies because we use this approach only in patients
with clinical evidence of N2 disease. It is not a routine pro-
cedure but is performed only in the presence of N2 disease. 
Regarding chest wall reconstruction, in these patients it
was possible to reconstruct the chest wall with muscle, so we
did not use any prosthetic material. Of course, we had a prob-
lem with the scapular tip in 1 patient, and we reoperated
merely to cut the scapular tip. However, I do not believe that
implanting a prosthesis would improve the postoperative
results in these patients.
We have used MRI only in the last patients we have treat-
ed this year and other years. Because of the organization at
our institution, it was possible to use MRI in all patients only
in the last 2 years. 
I cannot answer the question regarding induction therapy in
patients with soft tissue involvement. Our results are good, so
perhaps we should not change our approach. This is a point
that must be addressed in the future. 
Regarding Dr Rice’s question, our approach may look too
radical. However, only 28 patients had involvement of only
the parietal pleura, and these patients perhaps should have
been treated with extrapleural dissection. Because it is very
difficult for a surgeon to understand the depth of invasion of
the tumor in advance, we used radical excision in every
patient. Some series say that the surgeon has to try extrapleur-
al resection initially and decide at what point he or she should
convert. However, tissue for frozen section examination is
very difficult to obtain intraoperatively. Therefore, the sur-
geon must sometimes base the decision on his or her experi-
ence, and it is difficult for a young surgeon or a less experi-
enced, less skilled surgeon to make the right choice. We have
decided to use this approach in every patient. 
Dr Rice. Have you ever done a chest wall resection for a
T1 or T2 lesion? 
Dr Cardillo. No. Peripheral lung tumor with attachment of
the tumor to the parietal pleura does not mean filmy adhe-
sions. If we find filmy adhesions between the tumor and the
pleura with a clear plane, of course we dissect. In another
series of around 49 cases that I reported, we used extrapleur-
al dissection because the adhesions were just filmy adhe-
sions, not a fixed mass to the tumor. The tumor with a fixed
mass has been addressed in the present series and we have
treated with chest wall resection. 
Regarding the question of Dr Allen, our results really are
impressive. Our statistician commented that these results are
“three times better than the others.” I do not know the reason
for that. Maybe peripheral lung tumors have less drainage to
the mediastinal node. We are sure that only 17 patients had
N2 disease—a very small number compared with the exten-
sive lymphadenectomy we have performed in every patient.
There may be other biologic reasons. However, these results
have impressed us and other colleagues besides you. 
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